



Covid-19 pandemic urges patients under buprenorphine and methadone maintenance treatment to craving and to parallel illicit drug use

<u>Alexandra Katsouli</u>¹, Anna Karasavidou¹, Panagiotis Papadopoulos¹, Vasilios Stavropoulos¹, Elena Batsiari¹, Sotiris Tasoulis², Ioannis A. Nellas², Petros T. Barmpas², Aristidis S. Veskoukis³, Maria Tsironi⁴, Christonikos Leventelis^{1,4}



¹Organization Against Drugs, Athens, Greece; ²Department of Computer science and Biomedical Informatics, University of Thessaly, Greece; ³Department of Nutrition and Dietetics, University of Thessaly, Trikala, Greece; ⁴Nursing Department, University of Peloponnese, Tripoli, Greece

Introduction

COVID-19 pandemic induces notable disturbances in almost every aspect of human life. Furthermore, it putatively leads to a worrying increase in craving, despite the proven effectiveness of medication-assisted treatment (MAT).¹ The clinical evaluation of craving is crucial in terms of the confinement of relapse risk that is affected by stressors related to biopsychosocial status or overdose.² On that basis, the aim of this study was to investigate factors that influence craving among patients under MAT with methadone and buprenorphine during COVID-19 pandemic crisis.

Materials and Methods

total, 463 patients under In methadone maintenance treatment (MMT/n=115) and maintenance buprenorphine treatment (BMT/n=348) completed the validated 5-dimension Heroin Craving Questionnaire (HCQ). A total craving score was obtained from the reversed sum of each dimension sub-score, ranging from 5-35. The higher the score, the higher the magnitude of craving. Methadone hydrochloride solution tablets mg/ml) (10 and of buprenorphine (2-8 mg) were used. The patients were divided according to medications for opioid use disorders (MOUDs) dose (mg/24h) into three groups, as follows:

Results

The demographic data of the participants are depicted 1. COVID-19 Table in significantly affected all craving dimensions for MMT and BMT patients, with COVID-19 verified cases having a greater score in each case (Figure 1). A regression tree for the total craving score was for constructed, each agonist (MMT – A, BMT – B) as presented in Figures 2. Concerning MAT patients, the most important factor for the determination of craving was "COVID-19 diagnosis", certified COVID-19 with achieving higher cases craving score.

Table 1. The demographic data of the patients MMT **BMT Parameters** Ν % Ν % 22.13 Female 30 26.32 77 Sex Male 84 73.68 271 77.87 18-30 0 0.00 7 2.15 Age >30-50 52.34 76.99 56 251 group >50-67 47.66 68 20.86 51 Area of Urban 104 91.23 267 78.76 21.24 residence Rural 10 8.77 72 COVID-Noninfected 19 data 72.17 87.93 83 306 12.07 Infected 32 27.83 42 Mean (±SD) Mean (±SD) 42.95±8.06 48.74±8.18 Age Age of onset 18.90±6.49 17.47±5.22 Years of drug use 17.99±8.34 16.31±9.64 (prior MAT) Years in MAT 10.34±6.45 6.58±4.81 BMI 24.71±4.54 25.56±16.01


Discussion – Conclusions

	Low	Moderate	High
MMT	2-45	45-85	>85
BMT	2-10	10-18	>18

The analysis was conducted using the R-programming language (v.4.1.2).

References

- Shircliff, K., Liu, M., Prestigiacomo, C., Fry, M., Ladd, K., Gilbert, M. K., Rattermann, M. J., & Cyders, M. A. (2022). Mixed methods prospective findings of the initial effects of the U.S. COVID-19 pandemic on individuals in recovery from substance use disorder. PloS one, 17(7), e0270582.
- Levander, X. A., Hoffman, K. A., McIlveen, J. W., McCarty, D., Terashima, J. P., & Korthuis, P. T. (2021). Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addiction science & clinical practice, 16(1), 72.



The present study presents increased craving in MAT patients following COVID-19 infection. Craving for infected patients with coronavirus was more intense than the non-infected, both for each dimension sub-score and total score. For MMT patients, craving was higher for those that were administered with the lower dose, and that had remained in MAT for 11 years. Regarding their BMT counterparts, craving was related only to urban area of residence, probably due to the observed "ceiling effect" of buprenorphine. In conclusion, the MOUDs dose, the residence area and the number of years in MAT are interrelated and affect total craving of MAT patients.

The authors declare no conflict of interest